OD-07656

DRUG3 trials

Sponsors

Odyssey Therapeutics Inc., Odyssey Therapeutics

Conditions

Blau SyndromeCrohn DiseaseInflammatory Bowel DiseasesModerately to Severely Active Ulcerative ColitisSpondyloarthritisUC - Ulcerative ColitisUlcerative ColitisUlcerative Colitis (UC)

Phase 1

Phase 1 Study to Investigate OD-07656 in Healthy Adult Participants

CompletedNCT06206811

Odyssey TherapeuticsBlau Syndrome, Crohn Disease, Inflammatory Bowel Diseases +2

Start: 2024-02-12End: 2024-11-25Updated: 2025-02-21

Phase 2

Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

RecruitingNCT06850727

Odyssey TherapeuticsUC - Ulcerative Colitis, Ulcerative Colitis (UC)

Start: 2025-06-02End: 2026-11-01Target: 57Updated: 2026-02-11

A Phase 2a, Two-Part, Open-Label and Randomized Study to Evaluate the Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Patients with Moderately to Severely Active Ulcerative Colitis

RecruitingCTIS2024-520201-39-00

Odyssey Therapeutics Inc.Moderately to Severely Active Ulcerative Colitis

Start: 2025-08-28Target: 47Updated: 2025-06-30